New EORTC studies activated in 2012
3 Jan 2013
EORTC trial 18081
Adjuvant peginterferon alpha-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group
Target Accrual: 1200 patients
Study Coordinator:
Alessandro Testori – Istituto Europeo Di Oncologia, Milano
EORTC trial 90101 – CREATE
Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET (“CREATE”)
Target Accrual: 582 patients
Study Coordinator:
Patrick Schoeffski – Universitair Ziekenhuis Gasthuisberg, Leuven
EORTC trial 55092
Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma
Target Accrual: 36 patients
Study Coordinator:
Ignace Vergote – Universitair Ziekenhuis Gasthuisberg, Leuven
EORTC trial 90111
Neoadjuvant afatinib based treatment strategies followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study
Target Accrual: 30 patients
Study Coordinator:
Jean-Pascal Machiels – Cliniques Universitaires St. Luc, Brussels
EORTC trial 65091 – 06093
Empirical versus pre-emptive antifungal therapy in patients with haematological malignancies. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups
Target Accrual: 556 patients
Study Coordinator:
Peter Donnelly – Radboud University Nijmegen Medical Centre, Nijmegen
EORTC trial 62092-22092
A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS)
Target Accrual: 256 patients
Study Coordinator:
Sylvie Bonvalot – Institut Gustave Roussy, Villejuif
EORTC studies soon to be opened (in regulatory process)
EORTC trial 75111
Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH/PHM: an open-label multicentre randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group
Target Accrual: 80 patients
Study Coordinator:
Hans P.M.W. Wildiers – Universitair Ziekenhuis Leuven, Leuven
40CRC – SPECTAcolor
An EORTC prospective screening initiative for the determination of molecular parameters for advanced colorectal cancer
Target Accrual: not applicable
Study Coordinator:
Gunnar Folprecht – Universitaetsklinikum Carl Gustav Carus, Dresden
EORTC trial 40091 – BOS 2
Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab in kras as perioperative treatment in patients with resectable liver metastases from wild type KRAS colorectal cancer
Target Accrual: 360 patients
Study Coordinator:
Stephane Benoist – Hopital De Bicetre AP-HP, Le Kremlin Bicetre
Bernard Nordlinger – CHU Ambroise Pare AP-HP, Boulogne-Billancourt
EORTC trial 40085
Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment
Target Accrual: 150 patients
Study Coordinator:
Marc Peeters – Universitair Ziekenhuis Antwerpen, Edegem
EORTC trial 40084-22084
A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma
Target Accrual: 950 patients
Study Coordinator:
Jean-Luc Van Laethem – Hospital Universitaire Erasme, Brussels
EORTC trial 26112
An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (Irradiance)
Target Accrual: 140 patients
Study Coordinator:
Kirsten Hopkins – University Hospitals Bristol NHS Foundation Trust, Bristol
Michael Weller – UniversitätsSpital Zürich, Zurich
EORTC trial 22055 – 08053
Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement – LUNG-ART
Target Accrual: 700 patients
Study Coordinator:
Cecile Le Pechoux – Institut Gustave Roussy, Villejuif
EORTC trial 21082
Progression free survival (PFS) comparison between suberoylanilide hydroxamic acid (SAHA, Vorinostat TM) in combination with bortezomib (Velcade TM) and SAHA alone in refractory or recurrent advanced CTCL. A randomized study.
Target Accrual: 189 patients
Study Coordinator:
Pablo Luis Ortiz-Romero – Hospital Universitario, Madrid
EORTC trial 20101
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma (H11), a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research Group
Target Accrual: 570 patients
Study Coordinator:
Martin Hutchings – Rigshospitalet, Copenhagen
John Bean
EORTC, Medical Science Writer
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023